Drug intelligence / Profile preview

naomaitai

Development stage: Unknown
Lead developer: Guilin Sanjin Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Naomaitai is a multi-ingredient traditional Chinese medicine (TCM) capsule developed and manufactured by Guilin Sanjin Pharmaceutical. It is formulated with 13 herbal components, including red ginseng, Panax notoginseng, Salvia miltiorrhiza, and Ginkgo biloba leaf, and is primarily used for the treatment of cardiovascular and cerebrovascular diseases, as well as neurological conditions. The product is approved in China under the registration number 国药准字Z19980094. As a complex herbal formulation, it functions through the synergistic effects of its various active constituents to improve blood circulation and neurological function.

Brand names: NaomaitaiNaomaitai Capsule脑脉泰胶囊
Other names: 脑脉泰

Beyond the preview

Go deeper on naomaitai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on naomaitai.

Explore the full profile